NCT04058535View on ClinicalTrials.gov

Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

December 22, 2020

Study Completion Date

December 22, 2020

Conditions
Neovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL

Eylea

Aflibercept

BIOLOGICAL

ALT-L9

Aflibercept biosimilar

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Alteogen, Inc.
All Listed Sponsors
lead

Alteogen, Inc.

INDUSTRY